SCHEMBL372916

SCHEMBL372916

O=C1CCC(Cc2ccccc2)(Cc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP2C9 P11712 1/20 0.50
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
OPRM1 P35372 3/20 0.40
OPRL1 P41146 3/20 0.40
NR3C1 P04150 2/20 0.39
AR P10275 1/20 0.39
GAA P10253 1/20 0.39
RECQL P46063 1/20 0.39
ELANE P08246 2/20 0.38
DDB1 Q16531 2/20 0.37
CRBN Q96SW2 2/20 0.37
POLB P06746 1/20 0.37
OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25259758 0.93 KMT2A (0.44) MEN1KMT2ACYP2C9MAOAMAOB
Ethylene SCHEMBL11700594 0.86 GAA (0.45) MEN1KMT2ACYP2C9LMNAL3MBTL1
SCHEMBL30613092 0.85 ALDH1A1 (0.41) MEN1KMT2ACYP2C9MAOAMAOB
SCHEMBL3413567 0.84 OPRL1 (0.61) MEN1KMT2ACYP2C9MAOAMAOB
Ethylene SCHEMBL11815876 0.82 KMT2A (0.42) MEN1KMT2ACYP2C9MAOAMAOB
SCHEMBL14379186 0.80 OPRL1 (0.50) MEN1KMT2ACYP2C9MAOAMAOB
SCHEMBL11474711 0.80 MEN1 (0.47) MEN1KMT2ACYP2C9MAOAMAOB
SCHEMBL28819418 0.78 LMNA (0.47) MAOAMAOBLMNAHTTNPSR1
SCHEMBL8347115 0.78 MAOA (0.54) MAOAMAOBHTTOPRM1OPRL1
SCHEMBL156160 0.78 MAOA (0.54) MAOAMAOBOPRM1OPRL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118851844-A Synthesis method of 4-aryl-1-butene compound 河南大学 2024-10-29 CN disclosed
EP-3560499-B1 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES ONCOHEROES BIOSCIENCES INC (US) 2024-03-06 EP disclosed
EP-1778240-B1 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES ONCOHEROES BIOSCIENCES INC (US) 2020-03-25 EP disclosed
EP-3560499-A1 DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES Boehringer Ingelheim International GmbH (DE) 2019-10-30 EP disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
EP-2275107-B1 Combinations for the treatment of diseases involving cell proliferation BOEHRINGER INGELHEIM INT (DE) 2016-10-05 EP disclosed
EP-1751118-B1 PYRIMIDINES FOR USE AS PLK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-12-03 EP disclosed
US-20140154527-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2014-06-05 US disclosed
US-20140154527-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2014-06-05 US disclosed
US-20060014751-A1 New 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-19 US disclosed
US-20060009457-A1 New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-12 US disclosed
EP-1599478-A1 DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-11-30 EP disclosed
US-20050261295-A1 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 US disclosed
EP-1598343-A1 2-Arylaminopyrimidine derivatives as PLK inhibitors Boehringer Ingelheim International GmbH (DE) 2005-11-23 EP disclosed
US-6861422-B2 Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-01 US disclosed
US-20050014761-A1 Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 2005-01-20 US disclosed
US-20050014760-A1 Methods of treating diseases or conditions using dihydropteridinone compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-20 US disclosed
WO-2004076454-A1 DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) 2004-09-10 WO disclosed
US-20040176380-A1 New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) 2004-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009457-A1 New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments PLPBP, CYP2D6, CYP2B6 MEN1 1967/4885KMT2A 3287/4885CYP2C9 83/4885
US-20050261295-A1 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents MKI67, CCNY, CCNO MEN1 4605/4885KMT2A 1672/4885CYP2C9 1864/4885
US-20040176380-A1 New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions QDPR, DHPS, DRD5 MEN1 919/4885KMT2A 4752/4885CYP2C9 133/4885
US-20050014760-A1 Methods of treating diseases or conditions using dihydropteridinone compounds QDPR, DHPS, DHFR MEN1 417/4885KMT2A 4527/4885CYP2C9 540/4885
US-20050014761-A1 Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions QDPR, DHPS, DHODH MEN1 690/4885KMT2A 4704/4885CYP2C9 129/4885
US-20060014751-A1 New 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments FPR1, QDPR, FPR3 MEN1 773/4885KMT2A 3265/4885CYP2C9 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.